Screener
Jazz Pharmaceuticals JAZZ EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Jazz Pharmaceuticals’s reported figures.
The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026. Open the filing →
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001232524-26-000025
FAQ
- What is Jazz Pharmaceuticals's EBITDA?
- Jazz Pharmaceuticals (JAZZ) reported EBITDA of $518M in Q1 2026.
- How has Jazz Pharmaceuticals's EBITDA changed year-over-year?
- Jazz Pharmaceuticals's EBITDA increased by 1238.5% year-over-year, from -$45.5M to $518M.
- What is the long-term trend for Jazz Pharmaceuticals's EBITDA?
- Over 3 years (2021 to 2024), Jazz Pharmaceuticals's EBITDA has grown at a 56.1% compound annual growth rate (CAGR), from $196.98M to $749.43M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Jazz Pharmaceuticals's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude